Compare Sempra Energy (SRE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sempra Energy vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sempra Energy trades at $82.38 (market cap $53.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Sempra Energy is far larger — about 7.2× Spyre Therapeutics Inc. Common Stock's market cap, and Sempra Energy pays a 3.19% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sempra Energy for 9 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SRE | SYRE | |
|---|---|---|
Market Cap | $53.86B | $7.52B |
Volume | 2,605,713 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $99.75 | $108.92 |
52-Week Low | $76.90 | $22.18 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $90.50B | $6.52B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sempra Energy (SRE) trades at $82.37, up 0.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong Q2 2026 earnings that beat expectations, with a net income margin of 16.83% and robust cash flow from operations of $5.4 billion in 2026. Recent developments include a 20-year LNG supply agreement with Petrobras and the opening of SoCalGas' new headquarters, signaling growth initiatives.
The outlook for SRE is positive, supported by analyst consensus with an 80.77% buy rating and a price target of $97.25, implying significant upside. Key opportunities include EPS growth guidance of 7–9% and strategic investments in Texas and LNG. Risks involve high capital expenditures, regulatory exposure, and interest rate sensitivity. The stock's current valuation at a P/E of 23.88 requires continued execution to justify further gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sempra Energy
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
